Verve Therapeutics

Verve Therapeutics is developing single-course gene editing medicines to address cardiovascular disease, with a focus on precision genetic editing technologies to lower LDL cholesterol and triglyceride levels. Their lead program, VERVE-101, targets heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.